Watada H, Kaneko S, Komatsu M, et al. - In Japanese patients with type 2 diabetes (T2D), researchers tested the safety and effectiveness of insulin degludec/liraglutide (IDegLira) compared with ≤ 50 U insulin degludec (degludec). For this investigation, Japanese individuals with T2D uncontrolled with basal or pre-mix insulin (20–50 units) were randomised (1:1) to receive IDegLira or degludec both with metformin. The highest dose was 50 dose steps (IDegLira) or 50 units (degludec). A total of 210 Japanese individuals have been randomised to IDegLira or degludec and completion rates were 100% and 93%, respectively. Data reported that mean change in body weight was –0.7 kg with IDegLira compared with 0.7 kg with degludec. According to this 26-week, double-blind, multicentre, treat-to-target trial, IDegLira gave superior HbA1c decreases vs ≤ 50U degludec, with weight loss and comparable hypoglycaemia rates and no unforeseen safety or tolerability issues. These findings indicate that for Japanese patients with T2D uncontrolled on basal or premixed insulin, this therapy could be an appealing alternative for intensification.